S_mimary Mutation and overexpression are the main activating mechanisms for the ras family of genes in human cancer and the variable tandem repeat (VTR) located at the 3' end of H-ras has been associated with this risk. In the present study, we have analysed the relative levels of expression of H-ras mRNA in 26 samples of squamous cell carcinomas of the head and neck (SCCHN) by competitive reverse transcription-polymerase chain reaction (competitive RT-PCR) and also investigated whether there is an association between ras expression and alterations in the 3'-VTR region. In addition, we have studied the incidence of point mutations in codon 12 of H-ras, codons 12 and 13 of K-ras and codon 61 of N-ras in 120 SCCHN samples. Our results indicate that only two samples carry mutations, both of which are located in codon 12 of K-ras, but that overexpression of the H-ras proto-oncogene is a frequent event in SCCHN [54% (14/26)] and is associated with a favourable prognosis: 3 of 14 patients with H-ras overexpression have died, whereas 9 of 12 patients with low levels of H-ras expression have died. We have also undertaken an analysis of these results together with our previous investigations on microsatellite instability and loss of heterozygosity in SCCHN, but no associations were found. We therefore conclude that ras mutations are an infrequent event in the progression of the SCCHN in the Western world, whereas overexpression of the H-ras proto-oncogene is a common event.
Genetic alterations in oncogenes and tumour-suppressor genes have been impLicated in the iniation, promotion and progression of cancer. The ras family of genes (H-, K-and N-ras) encode a 21 kDa membrane protein (p21) which possesses GTPase activity and participates in a signal transduction pathway (Boguski and McCormick, 1993) . Hotspots for ras mutations are found in codons 12, 13 and 61, causing the mutant protein to lose its ability to exchange GTP with GDP; thus, it binds GTP with higher affinity and remains activated (Barbacid, 1987) . Mutational activation of the ras family genes has been reported in a wide range of human malignancies: 90% of pancreatic and 40% of colonic carcinomas harbour a mutation in K-ras and 50% of bladder carcinomas have H-ras mutations (Bos, 1989) . Overexpression of the normal alleles of ras genes can also transform cell lines in vitro (Spandidos and Wilkie, 1984) and have been reported in a number of cancers, such as breast and colon cancer and squamous cell carcinoma of the head and neck (SCCHN) (Field and Spandidos, 1990) . High levels of p21 have been postulated to activate other genes (including oncogenes such as myc, jun and fos) that are functionally downstream of ras and regulate normal cell growth and differentiation.
In addition to mutations and overexpression of ras genes, other genetic alterations have been described and shown to be associated with the development of human tumours. Loss of heterozygosity (LOH) of the H-ras locus has been reported in a number of carcinomas (Shiraishi et al., 1987; Garcia et al., 1989; Vachtenheim et al., 1994) , including SCCHN (Howell et al., 1989; Sheng et al., 1990; Kiaris et al., 1994) , and it has been proposed that the normal H-ras gene may possess tumour-suppressor as well as oncogene functions . Recently, we reported that genetic instability of a repetitive element which is located within intron 1 of H-ras is associated with the nodal status of patients with SCCHN (Saranath et al., 1991) and is most likely to be associated with the chewing of tobacco. Although ras mutations are considered to be rare events in the Western world (Field, 1992 , for a review), overexpression of ras family genes has been reported by a number of investigators. Spandidos et al. (1985) demonstrated elevated levels of H-ras and K-ras mRNA in all of the 14 SCCHN samples studied, but no correlation was found with clinicopathological parameters (Field et al., 1986) (Scambia et al., 1994) .
In the present study, we have analysed the overexpression of H-ras mRNA in SCCHN using competitive reverse transcription PCR (Foley et al., 1993; Kotsinas et al., 1994 5'-GACGGAATATAAGCI3GGTGG3' 3'-TAACTACCCCTCTGCACGGA-5' K-ras codons 12 and 13 5'-ACTGAATATAAACTTGTGGTAGTTGGACCT-3' 5'-TCAAAGAATGGTCCTGGACC-3' N-ras codon 61 
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Among the 120 samples analysed, only two were found to contain a ras mutation, both of which were in codon 12 of K-ras (Figure 2) . No mutations were found in codon 13 of K-ras, codon 12 of H-ras, or codon 61 of N-ras. These results are in agreement with previous studies, which show less than 5% ras mutations in SCCHN in the Western world (Tables H and III (UICC, 1978) . ND, no data. the tumour samples by their H-ras mRNA levels of expression into two groups; patients in the first and second groups exhibited < 1.5-and > 1.5-fold expression of H-ras, respectively, compared with normal tissue. Thus 14 of the 26 (54%) SCCHN specimens tested showed overexpression of H-ras mRNA, but no association was found with site, histology, TNM staging or positive nodes at pathology (Table IV ). An association was found, however, between the klvels of expression of H-ras and the clinical outcome; 9 of the 12 patients with no evidence of H-ras overexpression have died, whereas 3 of the 14 patients with elevated expression of the H-ras proto-oncogene are dead (log-rank analysis, x2 = 4.27, P<0.05). This result should be treated with caution as a number of these patients have been followed up for under 1 year (median 13 months, range 1-87 months). PCR amplification of the 3'-VTR region was only possible in 14 of the 26 patient samples owing to technical difficulties with some of the specimens. In 5 of 14 (36%) SCCHN paired samples, a different pattern was observed in the tumour specimens compared with their normal tissu counterparts, indicating genetic instability of the VTR region. (Some of these results have been previously reported in Kiaris et al., 1994.) No association with clinicopathological paraiitrs was demonstrated. An interesting observation was that, among the five SCCHN tumour specmens with VTR genetic instability, four had altered levels of H-ras mRNA compared with their normal tisse; two had lower levels (0.8 and 0.9) and two had higher levels (7.5 and 3.3). This may indicate that, at least in a certain number of patients, deregulation in the expression of H-ras is due to destabilisation of the VTR region of the gene.
Head and neck cancers are the sixth commonest cancers in the world but have a wide geographical variation which is most likely due to specific environmental risk factors (Vokes et al., 1993). This is re in the different incidence of ras Competitor H-rar; (b) target H-ras.
mutations in the Western world compared with SE Asia and India. In the Western world, ras mutations in SCCHN are very rare (< 5%), whereas in India 35% of SCCHN patients harbour a mutation in H-ras, and this has been associated with tobacco chewing (Saranath et al., 1991) . In Taiwan, 18% of oral cancer patients investigted were found to have a K-ras mutation, and these patients chew betel quid but do not use tobacco (Kuo et al., 1994) . In this study, 120 samples were analysed for mutations in codon 12 of H-ras, codons 12 and 13 of K-ras and codon 61 of N-ras, but only two of these samples (1.8%) contained ras mutations, both of which were found in codon 12 of K-ras. This is the largest analysis to date of ras mutations in SCCHN and the results confirm that ras mutations in SCCHN are rare in the Western world (Table HII) .
The expression of H-ras mRNA in SCCHN was investigated by competitive RT-PCR, which is a fast and sensitive technique for the interpretation of the klvels of specific tniscripts in cells or tissue. This is the first report to our knowledge that employs competitive RT-PCR for the investigation of H-ras mRNA expreson in tumour tissues. In the past, Northern blot and dot blot hybridisation techniques have been used, but they have the disadvantages of being ime-co ing and requiring the use of radioactivity. The primers used for H-ras cDNA amplification lie in adjacent exons of the H-ras gene, and thus it is possible to dis-H Kians et 127 criminate against contamination of the target RNA with genomic DNA. This particular feature of the amplification reaction and the co-amplification of the internal control (pGEM22OH-ras) produces increased specificity and accuracy of results (Kotsinas et al., 1994) . Significntly elevated levels of H-ras mRNA were found in 14 of the 26 (54%) SCCHN specimens tested, and in four (15%) patients the levels of H-ras mRNA were lower in the tumour than in the normal tissue. No association was found between the levels of expression of H-ras and the site of the tumour, TNM staging, histology or the nodal status of the patients, suggesting that, although overexpression of the Hras proto-oncogene is associated with the development of SCCHN, alterations in other oncogenes or tumoursuppressor genes (TSGs) may be more important for the progression of this disease. The four TNM stage I tumours investigated in this present study all exhibited elevated levels of H-ras mRNA (>1.5-fold), which may indicate that the overexpression of this proto-oncogene is important in the early stages of the disease. In vitro studies have suggested that H-ras overexpression is associated with morphological transformation, but tumorigenicity is also greatly increased when it is accompanied by the overexpression of K-ras and N-ras (Coleman et al., 1994) . The association of H-ras overexpression in SCCHN with a favourable prognosis is in agreement with an earlier immunohistochemical analysis of ras p21 in 69 SCCHN samples .
We have previously reported LOH at the H-ras locus . Three of the specimens that exhibited LOH were used in the present study, but no association between LOH at H-ras and overexpression of the gene was found. This result is in agreement with Sheng et al. (1990) , who also demonstrated no association between overexpression of mRNA and LOH at the H-ras locus in 11 SCCHN specimens. However, the transcriptional activation of H-ras still remains a puzzle. The lack of a TATA box and the presence of a CAAT box in the GC-rich promoter at the 5' end of the gene reveals similarities with other housekeeping genes (Breathnach and Chambon, 1981; Honkawa et al., 1987) . If overexpression of H-ras was due solely to the high proliferative status of cancer cells, then normalisation of the quantity of H-ras mRNA with actin mRNA (which is also a housekeeping gene) would equalise any differences between normal and tumour tissue from the same patient. However, the relative levels of expression ranged from 0.8 to 8.1, and this probably indicates that specific genetic alterations in particular tumour samples activate or inactivate H-ras protooncogene expression.
The VTR region in the 3' end of H-ras possesses differential enhancer activity (Spandidos and Holmes, 1987) and may divide the SCCHN population into certain subgroups which have an increased risk of developing cancer (Krontiris et al., 1993 ). Since we have already reported that instability occurs in a repetitive element (HRMS) located in intron 1 of H-ras , we considered that genetic instability in the 3'-VTR region of H-ras may also be a possibility, thus resulting in the generation of new VTR alleles within the tumours of patients. This may explain, at least in a certain number of samples, the deregulation of H-ras gene. Indeed, we did find that 5/14 (36%) patients exhibited 3'-VTR instability, confirming the suggestion that the H-ras VTR is a potential target for instability. However, the levels of H-ras mRNA were not associated with instability of the 3'-VTR region; two tumours exhibited overexpression (7.5 and 3.3 times) and two had relatively lower levels of H-ras mRNA (0.8 and 0.9 times). This may indicate that instability of the 3'-VTR region could influence the regulation of the H-ras gene in vivo, as previously proposed after in vitro experiments (Green and Krontiris, 1993) . However, a combined analysis of H-ras expression and instability of the VTR region in a larger number of patients is required to extend this observation.
Our study confirms the proposal that ras gene mutations are rare in SCCHN in the Western world but that overexpression of H-ras is associated with the development of SCCHN, however, the interpretation of this finding remains unclear. Further investigations should aim to clarify the significance of elevated transcription of the H-ras protooncogene and also to distinguish the mechanism(s) that results in the aberrant expression of H-ras in SCCHN. Finally, the present study illustrates the power of the competitive RT-PCR as a fast and sensitive technique for screening a relatively large number of samples for specific mRNA expression.
